Evaluation of Prognostic Factors in Triple Negative Breast Cancer Patients with Emphasis on Angiogenesis

Mumtaz Ahmad Ansari[1], Anand Kumar[2], Afreen Ali[3], Awgesh Kumar Verma[3], Mohit Mangla[3], Pratik K. Jha[3] and Vivek Srivastava[4]*

[1]Professor, Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, U.P., India
[2]Ex. Professor, Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, U.P., India
[3]Junior Resident, Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, U.P., India
[4]Associate Professor, Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, U.P., India; vivekims97@gmail.com

Abstract

Developing new therapeutic methods and exploring other possible future strategies in Triple Negative Breast Cancer (TNBC) is an area of interest. Angiogenesis is one such sought for area that can even serve as a targeted therapy in this subset of breast cancer. The objective of the study was to evaluate the prognostic factors in TNBC patients with emphasis on angiogenesis. Prospectively 120 patients with histologically confirmed breast cancer from June 2015 to July 2019 were included. The Colour Doppler evaluation of breast lump and axilla in terms of RI, PI and Vmax was done. Patients were categorized as having 'high' or 'low' RI, PI and Vmax on the basis of their mean value. Immunohistochemistry (IHC) was performed on viable tumour blocks obtained from mastectomy specimen using CD31 vascular endothelial staining. The idea was to obtain Microvascular Density (MVD) by counting all immunostained vessels at magnification of 400x. The association between TNBC and non TNBC with well-known Doppler parameters, tumour size, clinical lymph node status, number of positive lymph nodes, tumour grade, stage of disease and hormonal receptor status was investigated. Also the association between high and low MVD with these prognostic parameters were evaluated. A total of 120 patients were included in the study with the mean age of 42.43 ± 7.73 years (range 30-65 years). The mean RI, PI and Vmax were 0.92 ± 0.26, 2.19 ± 1.84 and 16.52 ± 10.70 respectively. The comparison between TNBC and non-TNBC with prognostic parameters showed significant association with age of patients, duration of disease, use of oral contraceptive pills (>1 year), tumour size, histological grade, RI and MVD ($p=0.041$, $p=0.011$, $p=0.002$, $p=0.029$, $p=0.026$, $p=0.014$ and $p=0.007$ respectively). The MVD value >13.17 (high) was found in 45 (37.5%) patients while 75 (62.5%) patients had low MVD value (<13.17). The high MVD (>16.52) was significantly associated with tumour size ($p<0.001$), axillary lymph node ($p=0.022$), clinical stage ($p=0.015$), histological grade ($p<0.001$), RI ($p<0.001$), ER status ($p<0.001$) and HER2 over expression ($p=0005$). TNBC is a subset of breast cancer showing aggressive biological behaviour as seen by presence of poor prognostic marker and increased vascularity.

Keywords: Colour Doppler, CD31, Micro-vessel Density, Triple Negative Breast Cancer

---

*Author for correspondence

1. Introduction

Breast Cancer (BC) has proven to be a heterogeneous disease with varying presentations, outcome, molecular characteristics, and chemotherapeutic response[1]. Various prognostic factors are identified in an effort to predict patient's fate in BC as a whole. The important factors among these are age of presentation, size of tumour, clinical or pathological stage, histology, tumour grade, lympho-vascular invasion, lymph node/distant spread and neoangiogenesis and/or lymphangiogenesis.

Tumours without expression of hormone receptors (Estrogen and Progesterone receptors) and human epidermal growth factor receptor 2 (HER2) are called triple negative breast cancer (TNBC). In terms of disease-free and overall survival they have a poor prognosis[2,3]. TNBC constitutes less than one fifth of all BC and is distinguished by its aggressive nature and insensitivity to targeted treatment approaches associated with endocrine and anti-HER2 therapies[4,5]. While TNBC is sensitive to chemotherapy, early recurrence with metastatic disease is usual, with poor prognosis[6]. It is therefore important to establish new treatment approaches and to research other putative targets in TNBC, such as angiogenesis[7,8].

Angiogenesis is important for BC growth and can be assessed by micro vessel density (MVD) measurement[9]. The potential of angiogenesis assessment also lies with its use for novel agents with antiangiogenic properties alone or in combination[10,11].

In the study done by Kumar et al.[12,13] preoperative Doppler ultrasound findings were shown to be helpful for the evaluation of intra-tumoural blood flow and was associated with histological grade and extent of breast cancer pathology. There is a clear evidence of significantly higher values of Resistivity Index (RI), Pulsatility Index (PI), and Maximum Flow Velocity (Vmax) in malignant breast lump compared to benign ones[14].

The aim of this study is to define the prevalence of triple negative status in this part of the country among BC patients coming to a tertiary care University hospital. The difference of established prognostic markers with special emphasis on vascularity as assessed by Colour Doppler and CD-31 Immunohistochemistry was investigated.

2. Methods

This was a prospective study undertaken on 120 patients of advanced breast carcinoma, who were operated primarily. Informed consent was taken from all the patients included in the study conducted in one surgical unit of the Department of General Surgery, Institute of Medical Sciences from June 2015 to July 2019.

The present work was approved by the Institute's Ethics Committee [No. Dean/2011-12/382], and all patients had received informed consent prior to the surgery. Patients who received any prior treatment in the form of chemotherapy, radiotherapy or breast surgery were excluded. Biopsy was taken from tumour and surrounding breast tissue using a 16 G Tru-Cut needle. Tissue specimen obtained was approximately 17 mm × 1 mm; 3-6 such pieces of tissues were collected. Preoperative demographic and clinical data, relevant investigations findings, Doppler study, details of pathological diagnosis, treatment details and follow-up period were collected prospectively in all the patients.

Colour Doppler of lump and axilla of breast was examined by an experienced radiologist using a 7.5 MHz Doppler (Xario Toshiba) probe to look for Resistivity Index (RI), Pulsatility Index (PI) and Maximum flow velocity (Vmax). Patients were categorized as having 'high' or 'low' RI, PI and Vmax depending on whether their individual RI, PI or Vmax was higher or lower than the mean RI, PI or Vmax value (Figure 2a, b).

Mastectomy specimen were cut into slices and fixed in 10% buffered formalin. The formalin fixed specimens were cut into 3μm section and stained with Hematoxylin and Eosin (H & E). After H & E staining these sections were evaluated under light microscopy for histopathological details – size, type and grade of tumour, number of lymph nodes dissected and number of positive lymph nodes, lymphovascular invasion and receptor status (ER, PR and HER2).

Figure 1. Distribution according to receptor positive and triple negative status.

a

b

Figure 2. (a) Colour Doppler of breast showing high RI value (b) Colour Doppler Study of breast showing relatively low RI, PI and Vmax.

Tumour representative blocks were selected for Immunohistochemistry (IHC) by staining with CD31. The primary antibody used was a monoclonal mouse anti human CD31 antibody from BIOGENEX, Netherlands and biotinylated goat anti-mouse antibody was used as the secondary antibody.

The 4 μm sections were taken on 1% Poly L-lysine coated slides. De-waxing was done by dipping the slides in Xylene-1 and then in Xylene-2 for five minutes and then rehydrated in absolute alcohol (95%) for 1-2 minutes. Antigen retrieval was done in microwave using citrate buffer (pH 6.0) at 95^0C and second at 97^0C for 10 minutes

each. Slides were washed in TRIS buffer (pH 7.6) followed by endogenous peroxidase blocking by 3% H_2O_2. Sections were finally incubated in primary antibody solution and washed. Diaminobenzidine dihydrochloride (DAB) chromogen was applied and then treated with secondary antibody. After final blotting and drying, slides were observed under microscope.

For determining the micro vessel density, Weidner criteria was utilized[15]. A vessel was defined if wall had endothelium with immunopositivity with CD31 and a vascular lumen. In the hotspot areas, usually at the periphery of the slides, highest stained areas were identified at low magnification (40X). Three such hotspots were selected at low magnification followed by counting of all CD31 immunostained vessels at 400x magnification to determine the MVD (Figure 3a, b). The mean value of MVD was observed by two investigators in each patient and in the case of interobserver differences of more than 30% in micro vessel count, the respective slides were reinvestigated by both observers using a discussion microscope. The mean of all values were taken and patients having higher MVD than mean value were considered as high and with values below the mean as low MVD.

The data analysis was carried out using the Social Sciences Statistical Package (SPSS), version 16.0. For continuous variables Student t test was used and Chi square and Fisher exact test were used for categorical variables. P-value < 0.05 was considered to be significant.

a

b

Figure 3. (a) Anti Human CD31 Antibody staining showing very high neovascularisation (b) Anti Human CD31 Ab staining showing relatively low neovascularisation.

3. Results

A total of 120 patients were included in the study with the mean age of 42.43±7.73 years (range 30-65 years). Majority of patients (65%) were pre-menopausal and rest were post-menopausal (35%). At the time of the presentation, lump was present in all the patients. The clinical and pathological characteristics of patients are presented in (Table 1). The Doppler parameters were classified according to their mean values. The mean RI, PI and Vmax were 0.92±0.26, 2.19±1.84 and 16.52±10.70 respectively. ER was positive in 39(32.5%) patients, PR in 57(47.5%) and HER2 was positive in 93(77.5%) patients. Thirty three (27.5%) patients were positive for both ER and PR. Overexpression of HER2-neu was found in 93(77.5%) patients. Fifty seven (47.5%) patients were both ER and PR negative (Figure 1).

Out of 120 patients, 21(17.5%) patients were triple negative. The comparison of various prognostic parameters between TNBC and non-TNBC is shown in (Table 2). Significant association were found in age of patients, duration of disease, use of oral contraceptive pills (>1 year), tumour size, histological grade, RI and MVD (p=0.041, p=0.011, p=0.002, p=0.029, p=0.026, p=0.014 and p=0.007 respectively) but no significant association were found in axillary lymph node, clinical

Table 1. Patient characteristics

Characteristics	
Age (years) <40 >40 Mean ± SD	45 (37.5) 75 (62.5) 42.43±7.73
Menopausal Status Premenopausal Postmenopausal	78 (65.0) 42 (35.0)
Duration of disease (months) <6 >6	51 (42.5) 69 (57.5)
Use of oral contraceptive pills (>1 year) Yes No	21 (17.5) 99 (82.5)
Tumour size (cm) < 6 cm > 6 cm Mean ± SD	48 (40.0) 72 (60.0) 6.32±2.36
Axillary node Positive Negative	90 (75.0) 30 (25.0)
Clinical stage Early (IIa+IIb) Advanced (III+IV)	48 (40.0) 72 (60.0)
Histological grade I + II III	78 (65.0) 42 (35.0)
Positive lymph nodes Negative Low (<6 lymph nodes) High (>6 lymph nodes)	21 (17.5) 18 (15.0) 81 (67.5)
ER Positive Negative	39 (32.5) 81 (67.5)
PR Positive Negative	57 (47.5) 63 (52.5)
HER2 Positive Negative	93 (77.5) 27 (22.5)
Resistivity Index High (>0.92) Low (<0.92)	69 (57.5) 51 (42.5)
Pulsatility Index High (>2.19) Low (<2.19)	39 (32.5) 81 (67.5)
Maximum flow velocity High (>16.52) Low (<16.52)	54 (45.0) 66 (55.0)

Microvessel density High (>13.17) Low (<13.17)	45 (37.5) 75 (62.5)
Breast cancer subtype TNBC NON-TNBC	21 (17.5) 99 (82.5)

Table 2. Comparison of Prognostic parameters between TNBC and non TNBC

Prognostic parameters	TNBC (n=21)	Non TNBC (n=99)	P value
Age (years) <40 >40	15 6	30 69	**0.041**
Duration of disease (months) <6 >6	18 3	33 66	**0.011**
Use of oral contraceptive pills (>1 year) Yes No	12 9	9 90	**0.002**
Tumour size (cm) <6 >6	0 21	48 51	**0.029**
Axillary node Positive Negative	18 3	72 27	0.656
Clinical stage Early (IIa+IIb) Advanced (III+IV)	6 15	39 60	0.591
Histological grade I-II III	6 15	72 27	**0.026**
Positive lymphnodes Negative High Low	3 15 3	18 66 15	0.964
Resistivity Index High (>0.92) Low (<0.92)	21 0	48 51	**0.014**
Pulsatility Index High (>2.19) Low (<2.19)	9 12	30 69	0.519
Maximum flow velocity High (>16.52) Low (<16.52)	6 15	48 51	0.336
Microvessel density High Low	18 3	27 72	**0.007**

stage, positive lymph nodes, PI, Vmax, ER, PR and HER2 overexpression.

The MVD was categorized (high/low) on the basis of their mean value. The mean MVD of 120 patients was 13.17. The MVD value >13.17 (high) was found in 45(37.5%) patients while 75(62.5%) patients had low MVD value (<13.17). The association between MVD (high and low) and clinic-pathological prognostic markers are shown in (Table 3). The high MVD (>16.52) was significantly associated with tumour size (p<0.001), axillary lymph node (p=0.022), clinical stage (p=0.015), histological grade (p<0.001), RI (p<0.001), ER status (p<0.001) and HER2 overexpression (p=0005).

Table 3. Comparison of Prognostic parameters between high and low MVD

Prognostic parameters	High MVD (n=45)	Low MVD (n=75)	P value
Age (years) <40 >40	13 32	32 43	0.131
Duration of disease (months) <6 >6	21 24	30 45	0.474
Use of oral contraceptive pills (>1 year) Yes 21 No 99	8 37	13 62	0.950
Tumour size (cm) <6 >6	9 36	39 36	**<0.001**
Axillary node Positive Negative	39 6	51 24	**0.022**
Clinical stage Early (IIa+IIb) Advanced (III+IV)	11 34	35 40	**0.015**
Positive lymphnodes Negative High Low	7 29 9	14 52 9	0.483
Histological grade I-II III	16 29	62 13	**<0.001**
Resistivity Index High (>0.92) Low (<0.92)	37 8	32 43	**<0.001**

Pulsatility Index High (>2.19) Low (<2.19)	17 28	22 53	0.339
Maximum flow velocity High (>16.52) Low (<16.52)	17 28	37 34	0.218
ER Positive Negative	27 18	12 63	**<0.001**
PR Positive Negative	23 22	34 41	0.539
HER2 Positive Negative	41 4	52 23	**0.005**

4. Discussion

TNBC represent a consistent subgroup of breast cancer with heterogeneous clinical presentation, clinical behaviour, histology and response to therapy. The etiological profile of TNBC that is associated with high mortality and insufficient therapeutic choices is little understood.

TNBC accounts for 10-20% of all BCs[3,6] worldwide and nearly 30% among Asian women population[16]. From India, Patil et al.[17] observed 19.9% to be TNBC in a cohort of 683 BC patients. Similarly, Ghosh et al.[18] reported TNBC status in 29.8% patients in 2008. In the present study, 32.5% patients were ER-positive, 47.5% patients were PR-positive, 93 (77.5%) patients were HER2 positive and 21 (17.5%) patients were found to be triple negative.

Studies have shown an increased incidence of TNBC in younger and black skinned women[6]. In their research with Asian women, Tan et al.[19] observed TNBC to more likely to present in patients with less than 40 years of age. Surprisingly, Indian published data showed large numbers of patients were even younger, i.e. <35 years. In the present study, 71.4% of patients in the triple negative group were also under 40 years of age, compared to just 30.3% in the non-triple-negative group (p=0.041). The mean age of presentation among the triple negative patients was 39.85 years.

Presentation as a lump in breast is common to both TNBC and non-TNBC alike. In western studies where mammographic screening is routine, TNBC is more likely to be identified by clinical examination than through serial imaging[20,21]. The reason for this paradox being a faster growth seen in TNBC which may miss tumour detection in fixed screening protocols. The possible reasons apart from missing tumour in between mammograms could be the variations in breast tissue density among TNBC phenotype making it more difficult to distinguish them on conventional mammography. We also found that a clinically detectable lump as presenting complain was seen in both TNBC and non-TNBC patients. The reasons may be the less use of mammography screening programs in this region of the country. On the other hand we found significantly larger proportion of TNBC patients presenting with shorter history of less than 6 months compared to non TNBC patients (85.7% versus 33.3% respectively, p=0.011). The association of breast feeding with occurrence of TNBC has also been studied but the results lack any conclusive statement. Studies vary from safety of occurrence of TNBC with breast feeding beyond 6 months[22,23] to no correlation of it to TNBC[24]. Parity and history of breast feeding was not correlated with the occurrence of TNBC and non TNBC in our analysis.

Extensive research has been carried out on the relationship between the use of oral contraceptives and BC risk but to a meagre number compared to other personal attributes like family history, early menarche, nulliparity and lack of breast feeding[25,26]. Oral contraceptive pills have shown to increase the chance of having BC as shown in a meta-analysis by Kahlenborn et al[27]. Studies have shown that the risk of developing cancer is more in young premenopausal women[28,29]. Duration of oral contraceptive use more than a year increases the risk of TNBC with a relative risk of 2.7[30]. In the present study, 9(9.1%) non-TNBC patients compared to 12(57.1%) TNBC patients used oral contraceptive pill for more than 1 year. This difference is significant but the small sample size limits drawing such conclusion from the present study.

The tumour size is ranked after the axillary lymph node status for deciding the prognosis in BC. This becomes single most important consideration if lymph nodes are not involved. Size is directly linked to an increased vascularity as well as the likelihood of having regional metastasis[31]. Dent et al., found that TNBC patients presented with larger lump size than non TNBC(7.77% T3 lesion compared to 1.12% T3 lesions in non-TNBC patients)[20]. We found that all patients with TNBC had a larger tumour size (> 6 cm) compared to only 51.5% of patients with non-TNBC (p=0.029).

The axillary lymph node status remains the single most important factors indicating the systemic spread and therefore distant metastasis[32]. However, the association

between TNBC status and lymph node spread is not well established[20,33-35]. Eighteen out of 21 TNBC patients (85.7%) had positive axillary lymph nodes compared to 72.7% of non-TNBC patients in the present study, but the association was not statistically significant (p=0.656). The lack of variation in our research may be explained by selection of the early stage of patients in which primary surgery was performed.

The grade of tumour has a direct link with TNBC as shown in studies[3,6,36]. Dent et al.[20] found that TNBC group are likely to have grade 3 tumours (66% versus 28%; P<0.0001). Study from India also observed that the TNBC was associated with a higher histological and nuclear grade compared to non-TNBC (p=0.001 and p=0.001)[19]. In present study, 15 (71.4%) of patients with TNBC had a high histological grade compared to 27 (27.3%) non-TNBC patients (p=0.026).

It has been reported that the use of colour Doppler ultrasonography in BC patients is useful in differentiating the tumour being benign or malignant[37]. The surrogate representation of Doppler for neovascularisation has been utilized[37,38]. The higher RI, PI and Vmax values of colour Doppler in more vascular lesions such as malignancy has been established[14]. Patients with malignant lesions usually exhibit enhanced colour Doppler signals due to neovascularisation of the tumour[37,39]. High values of these indices can successfully predict malignancy in a breast lump and the resistance caused due to presence of tumour itself or its emboli can cause an increased resistance affecting all the three variables[40,41]. Study published by Wang et al.[41] demonstrated a relationship between the power Doppler index and the levels of VEGF protein emphasizing the role of pre-operative colour Doppler assessment. High-grade and negative hormone receptors are shown to be associated with presence of marked vascularity[42]. While analysis by Kojima et al., found that the TNBC patients had fewer colour spots or vessel structures and rarely show significant vascularization (12.5%)[43]. Similarly, Lacroix et al.[44] found no association between the parameters of the colour Doppler and the TNBC. The RI, PI, and Vmax were obtained in all patients in the present study. When comparison was made between patients with TNBC and non-TNBC, RI was found to be high (>0.92) in patients with TNBC (p=0.014), however when PI and Vmax could not be related.

Angiogenesis and lymphangiogenesis are essential to the development, invasion, and metastasis of tumours[45]. Recent researches have shown that intratumoural MVD

is a significant predictor of BC survival and for predicting systemic metastasis risk[46]. Neovascularisation assessment can also be used as a valuable method in the preoperative prognosis of BC patients. In their study, Mohammed et al.[9] found 57 out of 99 TNBC cases with high MVD, compared with 108 out of 334 non-TNBC cases (p<0.001). In the present study, CD31 antibody has examined histological slides for angiogenesis assessment. The mean MVD was 13.17±4.13. Eighteen (85.7%) TNBC patients had high score as compared to 27 (27.3%) of non TNBC patients (p=0.007).

In this study, we also have determined angiogenesis in all the BC patients by counting micro vessels using anti-CD-31 antibody and compared MVD that we have obtained from each patient with prognostic factors. We found a statistically significant association between tumour size and MVD (p<0.001). This is consistent with some published studies[46-49] while some studies found no significant association between MVD and tumour size, and some studies reported an inverse association among them[50-52]. When comparing MVD with involvement of axillary lymph nodes, we observed that MVD was higher in patients with positive axillary lymph nodes relative to patients without axillary lymph nodes (p=0.022). In similarity to our findings, several studies have found that high MVD is associated with metastases of the axillary lymph nodes[48,49,53,54]. Nonetheless, some other studies have also found no association between MVD and metastases of the axillary lymph node[50,55].

We found a statistically significant relationship between advanced tumour stage (III+IV) and MVD stage (p=0.015) but no statistically significant relationship between lymph node positivity (high) and MVD (p=0.483) was observed. Comparing MVD to histological grade, we observed that MVD was higher in patients with a higher histological grade (grade III) compared to those with grade I+II (p<0.001). Strong literature studies[50,54,56] are available, and some research[57] find no significant association between MVD and histological grade.

We found a statistically significant association between high RI and MVD (p<0.001). When comparing MVD with PI and Vmax, no significant association was observed (p=0.339 and p=0.218).

We also found a statistically significant relationship between ER positives and HER2 overexpression and MVD (p<0.001 and p=0.005 respectively) in BC patients. But between PR and MVD (p=0.539) there was no statistically significant association observed. Several

studies have found a significant association between high MVD and oestrogen receptor[50,51] and overexpression with HER2[58]. However, some studies have reported that there is no association between MVD and ER, PR and HER2/neu receptor status[56].

We found no association in our analysis between MVD and the age of the patient, duration of the disease, use of oral contraceptive pills (> 1 year), positive lymph nodes, PI, Vmax and PR. Some studies have reported, in the literature, that there is no relationship between MVD and patient age[49,54,56] and PR[49,56].

In studies published in literature the correlation between MVD and prognostic parameters is variable. One explanation for this may be the use of various antibodies to highlight the microvessels[53,59,60]. We used the monoclonal antibody anti-CD31 to calculate the MVD and no other antibody hence we are not sure whether that selection influenced our tests. The MVD method of measurement may be another explanation for getting different results. The approach employed by Weidner is used in many microvessel count studies[50,57,61]. Some writers counted a single area under x200 or x250, while others counted one area under x400 magnification[62–64]. In this analysis, we have used Weidner's system of microvessel counting.

Different cut-off values used to identify patients according to their MVD may be another explanation for the different findings between studies. Many studies define the cutoff value as the average number of microvessels[56,65], while in other research, the cut off value is the median number of microvessels[66,67]. Also certain other studies accept absolute values as the cut-off value[62,68,69]. We accepted the mean number of micro vessels as the cut-off value in this study. By influencing the p value, all these various cut-off values may be the principal cause of different outcomes.

5. Conclusion

In conclusion, TNBC is not unusual as revealed in the present analysis. Triple negative cases have high vascularity and are aggressive. In comparison to non-triple negative cases, TNBC have increased presence of poor prognostic markers. The authors also conclude the need for a multicentric study with larger number of patients and a long follow-up to confidently label TNBC status in comparison to its Non-TNBC counterpart.

6. Funding

None

7. Conflict of Interest

None

8. References

1. Rakha EA Chan S. Overview Metastatic Triple-negative Breast Cancer. Clin Oncol 2011; 23: 587–600. https://doi.org/10.1016/j.clon.2011.03.013

2. Haffty BG, Yang Q, Reiss M, *et al*. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652–5657. https://doi.org/10.1200/JCO.2006.06.5664

3. Rakha EA, Sayed ME Green RA *et al*. Prognostic Markers in Triple-Negative Breast Cancer. Cancer 2007; 109: 25–32. https://doi.org/10.1002/cncr.22381

4. Bauer KR, Brown M, Cress RD *et al*. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721–1728. https://doi.org/10.1002/cncr.22618

5. Rhee J, Han SW. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008; 8: 307–312. https://doi.org/10.1186/1471-2407-8-307

6. Carey LA, Perou CM, Livasy CA *et al*. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492–2502. https://doi.org/10.1001/jama.295.21.2492

7. Cleator S, Heller W. Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235–244. https://doi.org/10.1016/S1470-2045(07)70074-8

8. Pal SK, Mortimer J. Triple-negative breast cancer: novel therapies and new directions. Maturitas. 2009; 20: 63(4): 269–274. https://doi.org/10.1016/j.maturitas.2009.06.010

9. Mohammed RAA, Ellis IO Mahmmod AM *et al*. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Modern Pathology 2011; 24: 774–785. https://doi.org/10.1038/modpathol.2011.4

10. Rayson D, Vantyghem SA, Chambers AF. Angiogenesis as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 1999; 4(4): 415–423. https://doi.org/10.1023/A:1018774618873

11. Browder T, Butterfield CE, Kraling BM *et al*. Antiangiogenic scheduling of chemotherapy improves efficacy against

experimental drug resistant cancer. Cancer Res 2000; 60(7): 1878–1886.

12. Kumar A, Singh S, Pradhan S, Shukla RC, *et al*. Doppler ultrasound scoring to predict chemotherapeutic response in advanced breast cancer. World Journal of Surgical Oncology 2007; 5: 99–110. https://doi.org/10.1186/1477-7819-5-99

13. Kumar A, Srivastava V, Singh S, *et al*. Colour Doppler ultrasonography for treatment response prediction and evaluation in breast cancer. Future Oncol 2010; 6(8):1265–1278. https://doi.org/10.2217/fon.10.93

14. Chao TC, Lo YF, Chen SC, *et al*. Colour Doppler ultrasound in benign and malignant breast tumours. Br Cancer Res Treat 1999; 57: 193–199. https://doi.org/10.1023/A:1006277617884

15. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8. https://doi.org/10.1056/NEJM199101033240101

16. Kim MJ, Ro JY, Ahn SH, *et al*. Clinicopathological significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER-2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37: 1217–1226. https://doi.org/10.1016/j.humpath.2006.04.015

17. Patil VW, Singhai R, Patil AV *et al*. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women 2011; 3: 9–19. https://doi.org/10.2147/BCTT.S17094

18. Ghosh J, Gupta S, Desai S *et al*. Estrogen, progesterone and HER2 receptor expression in breast tumours of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian journal of cancer 2011; 48: 391–396. https://doi.org/10.4103/0019-509X.92245

19. Tan GH, Taib NA, Choo WY *et al*. Clinical Characteristics of Triple negative Breast Cancer: Experience in an Asian Developing Country. Asian Pacific J Cancer Pre 2009; 10: 395–398.

20. Dent R, Trudeau M, Pritchard KI *et al*. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045

21. Collett K, Stefansonn IM, Eide J *et al*. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumours. Cancer Epidemiol Biomarkers Prev 2005; 14: 1108–1112. https://doi.org/10.1158/1055-9965.EPI-04-0394

22. Millikan RC, Newman B, Tse CK *et al*. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109**:** 23–39. https://doi.org/10.1007/s10549-007-9790-6

23. Phipps A, Malone K, Porter P *et al*. Reproductive and hormonal risk factors for postmenopausal luminal, Her-2-overexpressing, and triple-negative breast cancer. Cancer 2008; 113: 1521–1526. https://doi.org/10.1002/cncr.23786

24. Yang X, Sherman M, Rimm D *et al*. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16: 439–443. https://doi.org/10.1158/1055-9965.EPI-06-0806

25. White E, Malone KE, Weiss NS *et al*. Breast cancer among young United States women in relation to oral contraceptive use. J Natl Cancer Inst 1994; 86: 505–514. https://doi.org/10.1093/jnci/86.7.505

26. Marchbanks PA, McDonald JA, Wilson HG *et al*. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025–2032. https://doi.org/10.1056/NEJMoa013202

27. Kahlenborn C, Modugno F, Potter DM *et al*. Oral contraceptive use as a risk factor for premenopausal breast cancer: a metaanalysis. Mayo Clin Proc 2006; 81: 1290–302. https://doi.org/10.4065/81.10.1290

28. Rookus MA, van Leeuwen FE. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet 1994; 344: 844–851. https://doi.org/10.1016/S0140-6736(94)92826-6

29. Rosenberg L, Palmer JR, Rao RS *et al*. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996; 143: 25–37. https://doi.org/10.1093/oxfordjournals.aje.a008654

30. Dolle JM, Daling JR, White E *et al*. Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. Cancer Epidemiol Biomarkers Prev 2009; 18: 1157–1166. https://doi.org/10.1158/1055-9965.EPI-08-1005

31. Donegan WL. Prognostic factors, stage and receptor status in breast cancer. Cancer 1992; 70(6 Suppl): 1755–1764. https://doi.org/10.1002/1097-0142(19920915)70:4+<1755::AID-CNCR2820701617>3.0.CO;2-G

32. Fisher ER, Anderson S, Tan-Chiu E *et al*. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001; 91: 1679–687. https://doi.org/10.1002/1097-0142(20010415)91:8+<1679::AID-CNCR1183>3.0.CO;2-8

33. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568–2581. https://doi.org/10.1200/JCO.2007.13.1748

34. Crabb SJ, Cheang MC, Leung S *et al*. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008; 8:249–256. https://doi.org/10.3816/CBC.2008.n.028

35. Tan DS, Marchió C, Jones RL, *et al*. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res

Treat. 2008; 111: 27–44. https://doi.org/10.1007/s10549-007-9756-8

36. Thike AA, Cheok PY, Jara-Lazaro AR et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010; 23: 123–133. https://doi.org/10.1038/modpathol.2009.145

37. Choi HY, Kim HY, Baek SY et al. Significance of resistive index in colour Doppler ultrasonogram: differentiation between benign and malignant breast masses. Clin Imaging 2000; 23: 284–288. https://doi.org/10.1016/S0899-7071(99)00152-7

38. Zhu Q, You S, Jiang Y et al. Detecting angiogenesis in breast tumourssss: comparison of colour Doppler flow imaging with ultrasound-guided diffuse optical tomography. Ultrasound in Med. & Biol 2011; 37: 862–869. https://doi.org/10.1016/j.ultrasmedbio.2011.03.010

39. Kook SH, Park HW, Lee YR, et al. Evaluation of solid breast lesions with power Doppler sonography. J Clin Ultrasound 1999; 27: 231–237. https://doi.org/10.1002/(SICI)1097-0096(199906)27:5<231::AID-JCU2>3.0.CO;2-P

40. Peters Engl C, Medl M, Leodolter S. The use of colour coded and spectral Doppler ultrasound in the differentiation of benign and malignant breast lesions. Br J Cancer 1995; 71: 137–139. https://doi.org/10.1038/bjc.1995.28

41. Wang Y, Dan HJ, Fan JH, et al. Evaluation of the correlation between colourpower doppler flow imaging and vascular endothelial growth factor in breast cancer. The journal of international medical research 2010; 38: 1077–1083. https://doi.org/10.1177/147323001003800335

42. Shin HJ, Kim HH, Huh MO, Kim MJ, Yi A, Kim H, t al. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive cancer. Br J Radiol 2011; 84: 19–30. https://doi.org/10.1259/bjr/92960562

43. Kojima Y, Tsunoda H. Mammography and ultrasound features of triple-negative breast cancer. Breast Cancer 2011; 18(3):146–151. `

44. Lacroix MB, Grogan GM, Debled M et al. Radiological features of triple-negative breast Cancers. Diagnostic and Interventional Imaging 2012; 93: 183–190. https://doi.org/10.1016/j.diii.2012.01.006

45. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003; 98: 413–423. https://doi.org/10.1002/cncr.11464

46. Choi WW, Lewis MM, Lawson D et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinico-pathologic parameters and VEGF-family gene expression. Mod Pathol 2005; 18: 143–152. https://doi.org/10.1038/modpathol.3800253

47. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F. Tumour microvessel density, p53 expression, tumour size, and peritumoural lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454–66. https://doi.org/10.1200/JCO.1994.12.3.454

48. Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjic N. Correlation between vascular endothelial growth factor, angiogenesis, and tumour-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 2002;440: 583–8. https://doi.org/10.1007/s004280100458

49. Şener E, Şipal S, Gündoğdu C. Comparison of Microvessel Density with Prognostic Factors in Invasive Ductal Carcinomas of the Breast. Comparison of Microvessel Density with Prognostic Factors in Invasive Ductal Carcinomas of the Breast. Turk Patoloji Derg 2016; 32(3): 164–170. https://doi.org/10.5146/tjpath.2016.01366

50. Bharti JN, Rani P, Kamal V, Agarwal PN. Angiogenesis in breast cancer and its correlation with estrogen, progesterone receptors and other prognostic factors. J Clin Diagn Res 2015; 9: 5–7. https://doi.org/10.7860/JCDR/2015/10591.5447

51. Biesaga B, Niemiec J, Ziobro M. Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group. Pathol Oncol Res 2012; 18: 949–60. https://doi.org/10.1007/s12253-012-9525-9

52. Tsutsui S, Kume M, Era S. Prognostic value of microvessel density in invasive ductal carcinoma of the breast. Breast Cancer 2003; 10: 312–9. https://doi.org/10.1007/BF02967651

53. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120–4. https://doi.org/10.1016/0140-6736(92)93150-L

54. Wang G, Liang Y, Zhang H, Wang L, XU J. Microvessel density recognized by Endoglin as prognostic markers in breast carcinoma. Journal of Materials and Applications 2014; 3: 41–6.

55. Kato T, Kimura T, Ishii N, Fujii A, Yamamoto K, Kameoka S, Nishikawa T, Kasajima T. The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long-term survival in Japanese patients with breast cancer. Breast Cancer Res Treat 1999; 53: 19–31. https://doi.org/10.1023/A:1006193024382

56. Erdem O, Dursun A, Coskun U, Gunel N. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative

breast carcinoma. Tumouri 2005; 91: 46–52. https://doi.org/10.1177/030089160509100109

57. Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodino C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 2003; 81: 159–68. https://doi.org/10.1023/A:1025755717912

58. Vogl G, Bartel H, Dietze O, Hauser-Kronberger C. HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer. Appl Immunohistochem Mol Morphol 2006; 14: 138–45. https://doi.org/10.1097/01.pai.0000168591.58721.a6

59. Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster SJ, Winstanley J. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 1997; 76: 1046–54. https://doi.org/10.1038/bjc.1997.506

60. da Silva BB, Lopes-Costa PV, dos Santos AR, de Sousa-Junior EC, Alencar AP, Pires CG, Rosal MA. Comparison of three vascular endothelial markers in the evaluation of microvessel density in breast cancer. Eur J Gynaecol Oncol 2009; 30: 285–8.

61. Kanjanapanjapol S, Wongwaisayawan S, Phuwapraisirisan S, Wilasrusmee C. Prognostic significance of microvessel density in breast cancer of Thai women. J Med Assoc Thai 2007; 90: 282–90.

62. Obermair A, Kurz C, Czerwenka K, Thoma M, Kaider A, Wagner T, Gitsch G, Sevelda P. Microvessel density and vessel invasion in lymph-node-negative breast cancer: Effect on recurrence-free survival. Int J Cancer 1995; 62: 126–31. https://doi.org/10.1002/ijc.2910620203

63. Axelsson K, Ljung BM, Moore DH 2nd, Thor AD, Chew KL, Edgerton SM, Smith HS, Mayall BH. Tumour angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995; 87: 997–1008. https://doi.org/10.1093/jnci/87.13.997

64. Medri L, Nanni O, Volpi A, Scarpi E, Dubini A, Riccobon A, Becciolini A, Bianchi S, Amadori D. Tumour microvessel density and prognosis in node-negative breast cancer. Int J Cancer 2000; 89: 74–80. https://doi.org/10.1002/(SICI)1097-0215(20000120)89:1<74::AID-IJC12>3.0.CO;2-L

65. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755–761. https://doi.org/10.1016/0046-8177(92)90344-3

66. Fridman V, Humblet C, Bonjean K, Boniver J. Assessment of tumour angiogenesis in invasive breast carcinomas: Absence of correlation with prognosis and pathological factors. Virchows Arch 2000; 437: 611–7. https://doi.org/10.1007/s004280000292

67. de Jong JS, van Diest PJ, Baak JP. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology 2000; 36: 306–12. https://doi.org/10.1046/j.1365-2559.2000.00850.x

68. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 1996; 86: 353–64. https://doi.org/10.1016/S0092-8674(00)80108-7

69. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996; 88: 1764–9. https://doi.org/10.1093/jnci/88.23.1764